TAK(Takeda Pharmaceutical Company Limited) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-03-31 | FY 截至 2022-03-31 | FY 截至 2023-03-31 | FY 截至 2024-03-31 | FY 截至 2025-03-31 |
|---|---|---|---|---|---|
| 营业收入 | $30.15B | $31.17B | $29.61B | $28.91B | $30.32B |
| 毛利润 | $20.77B | $21.50B | $20.46B | $19.23B | $19.87B |
| 营业利润 | $4.80B | $4.02B | $3.61B | $1.45B | $2.27B |
| 净利润 | $3.54B | $2.01B | $2.33B | $976.74M | $714.35M |
| 经营现金流 | $9.53B | $9.81B | $7.18B | $4.86B | $7.00B |
| 自由现金流 | $8.48B | $8.73B | $6.15B | $3.67B | $5.67B |
| 摊薄每股收益 | $2.25 | $1.27 | $1.48 | $0.62 | $0.44 |